Long COVID : New Treatment Perspective Using Nutraceuticals

Coronavirus disease (COVID-19) is an ongoing worldwide pandemic affecting a large population regardless of gender, age, and ethnicity. The persistence of the COVID-19 symptoms has become a significant health issue and is collectively called “Long COVID.” It can be described as the presence of symptoms of COVID even after the recovery from the viral infection. The prolonged symptoms in the patients could be due to various reasons and factors. Prolonged fatigue is a common symptom of Long COVID in patients even after they have recovered from the viral infection. Currently, only rehabilitation has shown promising results in managing the symptoms of Long COVID. Although pharmaceutical drugs have shown potential in treating the symptoms of Long COVID, more clinical evidence is required to confirm its treatment with less to no side effects; since it’s a new disease, the in-depth knowledge of the same is still evolving. Another healthier approach to treating the symptoms of Long COVID could be dietary supplements or “Nutraceuticals,” identified as an alternative to pharmaceuticals, including nutritional supplements, derived nutrients, and dietary and herbal products that display physiological advantages. Nutritional strategies can also play a role in treating hospitalized patients as maintaining the immune system is critical to combat viral infection.Nutraceuticals may be a practical and healthier approach to managing the symptoms of Long COVID or COVID-19. Although ample clinical evidence is present for the treatment of symptoms of COVID-19, further studies in treating Long COVID or its symptoms are required

S-amlodipine--the 2007 clinical review.

S-amlodipine is the only vaso-active enantiomer of amlodipine. This article reviews the published data in nearly 5000 patients. Randomised controlled trials of S-amlodipine at half the dose of racemate in the treatment of hypertension, have shown it to be as effective as racemic amlodipine. The postmarketing surveillance studies (n = 4089) of S-amlodipine confirmed its antihypertensive efficacy and showed that the incidence of peripheral oedema is negligible with S-amlodipine compared to racemic amlodipine. Further, the patients with peripheral oedema who were switched over from racemic amlodipine to S-amlodipine resolved their oedema associated with the racemate, while sustaining the blood pressure control. Subgroup analyses showed S-amlodipine to be effective and safe in elderly hypertensives and isolated systolic hypertension patients. A clinical study in normotensive angina patients confirmed the anti-anginal efficacy of S-amlodipine at half the dose of racemate. Fixed-dose combinations of S-amlodipine with atenolol and S-amlodipine with hydrochlorothiazide have been shown to be effective and well tolerated in clinical practice. In the light of its efficacy and favourable tolerability profile, S-amlodipine used alone or in combination with other antihypertensive or anti-anginal drugs, is a valuable treatment option in the management of hypertension and angina.